Latest Conference Articles

Why Investment Strategies Matter for Advancing Pharmaceutical Technologies

November 7th 2025

PharmSci 360 will spotlight the economics behind AI, scale-up, and advanced modalities, addressing cost barriers that influence future drug manufacturing.

AAPS PharmSci 360: Enhancing Bioanalysis with AI and Other Technologies

November 7th 2025

Pharmaceutical Technology® spoke with Dr. Mark Arnold, owner and principal, Bioanalytical Solution Integration, ahead of AAPS PharmSci 360 to find out how bioanalysis enhances bio/pharmaceutical drug development.

AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis

November 7th 2025

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss how LC–MS is used in bioanalysis.

How AI, Machine Learning, and Large Language Models Enhance Bioanalysis

November 7th 2025

Long Yuan, PhD, director of the Department of Drug Metabolism and Pharmacokinetics at Biogen, explains how artificial intelligence, machine learning, and large language models are used in performing bioanalysis.

2025 AAPS PharmSci 360 to Highlight Next-Gen AI for Drug Development

November 7th 2025

AAPS PharmSci 360 will spotlight AI advances, gene therapy progress, and leading pharma research insights this year, says programming chair Mei He.

Building Trusted CDMO Relationships: A CPHI Conversation with Thermo Fisher Scientific, Part Two

November 7th 2025

CPHI Europe

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and the overall experience of attending the CPHI conference.

Regulatory, cGMP, and CDMO Challenges: A CPHI Conversation with Lonza Capsugel, Part Two

November 7th 2025

CPHI Europe

Frank Romanski of Lonza Capsugel dives into the excipient side of manufacturing and the emerging prevalence of digitalization.

New Dosage Forms and Delivery Systems Driving 505(b)(2) Success

November 6th 2025

Analysis of FDA 505(b)(2) data (2024–2025) shows 69 drug reformulations, with a focus on enhancing stability and patient comfort, utilizing new dosage forms, and innovative strategies.

Building Resilience in Pharma: Our Top 10 Questions from CPHI Frankfurt

November 5th 2025

CPHI Europe

Exclusive interviews revealed that digital transformation, data integrity protocols, and a regionalized supply chain are crucial strategies for optimizing drug development and manufacturing efficiency.

Outsourcing Partners Providing End-to-End Service

November 4th 2025

Christian Dowdeswell, managing director, Arcinova, a Quotient Sciences company, discusses what makes a CDMO that offers end-to-end service beneficial.